ArticleScientific reports2025
Pan-cancer landscape of cellular senescence heterogeneity reveals associations with prognosis and therapy response.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cellular senescence (CS) plays an important role in cancer development and treatment. However, the heterogeneity of CS among different types of cancer and its impacts on patient prognosis and therapy response remain to be fully elucidated. This study performed a comprehensive pan-cancer analysis on the CS landscape of 33 cancer types and 29 normal tissues. The molecular subgroups of CS were identified based on the expression of CS-related genes. Multi-platform data including prognosis, microbiota, immune microenvironment, multi-omics, and drug sensitivity were used to investigate the associations with the CS subgroups. Additionally, 12 single-cell datasets and 19 immunotherapy cohorts were collected to evaluate the CS subgroups. We characterized five pan-cancer CS subgroups with distinct biological features, named Inflamm-aging, DNA Damage Response, Autophagy, Immunologically Quiet, and Metabolic Disorder. The CS subgroups showed cancer-type and tissue-type specific distribution, and revealed significant associations with cancer prognosis, intratumoral microbiota, immunophenotypic features, and multi-omic alterations. The immunophenotypic features of the CS subgroups were verified by immunohistochemistry staining in tissue microarrays. Single-cell analyses indicated the CS heterogeneity among cancer types at the single-cell level. Furthermore, we developed a machine-learning model integrating CS-related cancer driver genes to infer the CS subgroups, and verified its prediction capability for immunotherapy response and prognosis in independent cohorts. Finally, potential therapeutic agents and targets were identified in the CS subgroups, which might have therapeutic implications for patients. Overall, this study provided a CS-derived classification scheme to expand the existing understanding of CS heterogeneity. The CS subgroups can reveal distinct CS states among cancer types and may contribute to improving personalized therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.